Antihypertensive drugs and insulin resistance in obesity

Internal Medicine

Volumn 44, Issue 5, 2005, Pages 395-396

  Mukasa, Koji ^a  

^a ITO HOSPITAL   (Japan)

Author keywords

Calcium channel blockers; Dehydroepiandrosterone; Hypertension; Insulin resistance

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; CORTICOSTEROID; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LEPTIN; MANIDIPINE; NIFEDIPINE; NITRENDIPINE; PRASTERONE; PRASTERONE SULFATE; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ADIPOSE TISSUE; ADRENERGIC ACTIVITY; CALCIUM CELL LEVEL; DRUG CHOICE; EDITORIAL; HORMONE METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SEX RATIO; STEROIDOGENESIS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; OBESITY; RISK FACTORS;

EID: 21244476406     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.395     Document Type: Editorial

References (24)

1. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 75: 809-817, 1985.
2. Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varricchio M. Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 18: 395-398, 1980.
3. Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 15 Suppl 5: S46-52, 1990.
4. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14 Suppl 4: 39-47, 1991.
5. Harano Y, Kageyama A, Hirose J, et al. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 44: 315-319, 1995.
6. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76: 1464-1469, 1993.
7. Beer NA, Jakubowicz DJ, Beer RM, Arocha IR, Nestler JE. Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76: 178-183, 1993.
8. Iimura O, Shimamoto K, Masuda A, et al. Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives. J Diabetes Complications 9: 215-219, 1995.
9. Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 43: 561-565, 2004.
10. Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 82: 1848-1852, 1988.
11. Suzuki M, Kanazawa A, Hasegawa M, Harano Y. Improvement of insulin resistance in essential hypertension by long-acting Ca antagonist benidipine. Clin Exp Hypertens 21: 1327-1344, 1999.
12. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women. J Clin Endocrinol Metab 79: 1077-1081, 1994.
13. Yen TT, Allan JA, Pearson DV, Acton JM, Greenberg MM. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids 12: 409-413, 1977.
14. Aoki K, Saito T, Satoh S, et al. Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1, 6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone. Diabetes 48: 1579-1585, 1999.
15. Mukasa K, Kanesiro M, Aoki K, et al. Dehydroepiandrosterone (DHEA) ameliorates the insulin sensitivity in older rats. J Steroid Biochem Mol Biol 67: 355-358, 1998.
16. Al-Harithy RN. Dehydroepiandrosterone sulfate levels in women. Relationships with body mass index, insulin and glucose levels. Saudi Med J 24: 837-841, 2003.
17. Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Horm Metab Res 33: 167-169, 2001.
18. Jedrzejuk D, Medras M, Milewicz A, Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male 6: 151-156, 2003.
19. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 88: 3190-3195, 2003.
20. Fukuzawa M, Satoh J, Ohta S, et al. Modulation of tumor necrosis factor-alpha production with anti-hypertensive drugs. Immunopharmacology 48: 65-74, 2000.
21. Kimura M, Tanaka S, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H. Dehydroepiandrosterone decreases serum tumor necrosis factor-alpha and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endocrinology 139: 3249-3253, 1998.
22. Yagi S, Goto S, Yamamoto T, Kurihara S, Katayama S. Effect of cilnidipine on insulin sensitivity in patients with essential hypertension. Hypertens Res 26: 383-387, 2003.
23. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 106: 2533-2536, 2002.
24. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 14: 103S-115S, 2001.